Kenta Biotech AG
  • Home
  • Shop
  • Events
  • Courses
  • Services
  • Pricing
  • Company
    • Blog
    • Success Stories
    • About Us
  • Appointment
  • Contact us
  • 0
  • +1 (718) 513-2983
  • Sign in
  • Contact Us
Kenta Biotech AG
  • 0
    • Home
    • Shop
    • Events
    • Courses
    • Services
    • Pricing
    • Company
      • Blog
      • Success Stories
      • About Us
    • Appointment
    • Contact us
  • +1 (718) 513-2983
  • Sign in
  • Contact Us
  1. Products
  2. Assay test kits
Public Pricelist
Public Pricelist
Sort By: Featured
Featured Newest Arrivals Name (A-Z) Price - Low to High Price - High to Low

Assay test kits

[0597-PCR-V049-96R] Avian leukosis virus Rous sarcoma virus detection Tests
Avian leukosis virus Rous sarcoma virus detection Tests
1,188.00 € 1188.0 EUR
[0597-Oneq-V049-150R] Avian leukosis virus Rous sarcoma virus detection Tests
Avian leukosis virus Rous sarcoma virus detection Tests
2,557.00 € 2557.0 EUR
[0812-SL0062BI] Avian Serum amyloid A (SAA) ELISA Test - 96 Tests
Avian Serum amyloid A (SAA) ELISA Test - 96 Tests
481.40 € 481.40000000000003 EUR
[0639-abx092015] Avian Influenza Virus Antigen Rapid Test Test - 40 tests
Avian Influenza Virus Antigen Rapid Test Test - 40 tests
589.00 € 589.0 EUR
[0639-abx364805-96] Avian Influenza Virus Antibody (AIV-Ab) ELISA Test - 96 tests
Avian Influenza Virus Antibody (AIV-Ab) ELISA Test - 96 tests
748.00 € 748.0 EUR
[0881-520005-96T] Atrazine, ELISA, 96 Tests
Atrazine, ELISA, 96 Tests
816.00 € 816.0 EUR
[0986-ab107922] Asparaginase Activity Assay Test - 100 Tests
Asparaginase Activity Assay Test - 100 Tests
749.00 € 749.0 EUR
[0002-0801199] Arylesterase/Paraoxonase Assay Test (200 tests)
Arylesterase/Paraoxonase Assay Test (200 tests)
603.00 € 603.0 EUR
[0149-ANXVKPE-100 Tests] Apoptosis Detection Test - 100 tests
Apoptosis Detection Test - 100 tests
412.00 € 412.0 EUR
[0270-PB-504-T100] Anti-Hu Ig Kappa Light Chain Pacific Blue 100 Tests
Anti-Hu Ig Kappa Light Chain Pacific Blue 100 Tests
443.20 € 443.2 EUR
[0270-1P-658-T100] Anti-Hu CD99 PE - 100 Tests
Anti-Hu CD99 PE - 100 Tests
281.00 € 281.0 EUR
[0270-PB-208-T100x2] Anti-Hu CD9 Pacific Blue - 100 tests x 2
Anti-Hu CD9 Pacific Blue - 100 tests x 2
613.00 € 613.0 EUR
[0270-PB-235-T025] Anti-Hu CD71 Pacific Blue - 25 tests
Anti-Hu CD71 Pacific Blue - 25 tests
182.00 € 182.0 EUR
[0270-1P-206-T100] Anti-Hu CD7 PE - 100 Tests
Anti-Hu CD7 PE - 100 Tests
331.00 € 331.0 EUR
[0270-T8-644-T025] Anti-Hu CD64 PE-Cy5 - 25 Tests
Anti-Hu CD64 PE-Cy5 - 25 Tests
166.00 € 166.0 EUR
[0270-1P-789-T100] Anti-Hu CD56 PE - 100 Tests
Anti-Hu CD56 PE - 100 Tests
331.00 € 331.0 EUR
[0270-1F-498-T100] Anti-Hu CD45R0 FITC - 100 tests
Anti-Hu CD45R0 FITC - 100 tests
249.00 € 249.0 EUR
[0270-1P-273-T100] Anti-Hu CD31 PE - 100 tests
Anti-Hu CD31 PE - 100 tests
281.00 € 281.0 EUR
[0270-1A-728-T100] Anti-Hu CD300e APC - 100 Tests
Anti-Hu CD300e APC - 100 Tests
381.00 € 381.0 EUR
[0270-1A-503-T100] Anti-Hu CD24 APC - 100 Tests
Anti-Hu CD24 APC - 100 Tests
381.00 € 381.0 EUR
  • 4
  • 5
  • 6
  • 7
  • 8

Clear Filters



Respiratory syncytial virus (RSV) infections are the most common cause of hospitalization in early childhood, accounting for 57 000 to 120 000 hospitalizations each year in the United States. RSV is causing annual epidemics of bronchiolitis and pneumonia worldwide. In most cases the infection with RSV heals without sequelae, yet RSV infection can cause lung function deterioration and in some circumstances, years of recurrent wheezing or asthma may ensue. Overall RSV accounts for an estimated2% of the hospitalization rate among infants less than 1 year of age. This rate increases 4–5-fold among high-risk patients such as premature infants and those with chronic lung disease or complicated congenital heart disease.


Currently there is only one possibility to prevent infections of at-risk patients with RSV, namely immuno-prophylaxis with palivizumab/Synagis, marketed by MedImmune. However, the response to palivizumab is variable among individuals, and sometimes palivizumab fails to prevent RSV infections effectively.


Due to the lack of better antibodies, lack of effective anti-viral treatment and lack of an effective preventive vaccine for RSV, there is a substantial medical need for more efficacious prophylactic immunizations, e.g. by antibody.


Kenta Biotech had developed a fully human monoclonal antibody (KBRV201) derived from B-cells of a human donor. KBRV201 is of the human IgG1 isotype with specificity and very high affinity for the F-protein of human respiratory syncytial virus (hRSV). KBRV201 has been tested for recognition and neutralization of hRSV strains -A, -B and –Long, and KBRV201 could neutralize in vitro all strains tested with higher efficacy than other anti-F-protein mAb.




KBRV201 successfully recognizes 22 clinical isolates from children infected with RSV, including one isolate with a mutated F-protein. Overall KBRV201 has demonstrated superiority in every experiment performed, and KBRV201 is currently undergoing extensive testing in animal models.

14009 NW Harbor Ln, Portland, OR 97229, USA.


Follow us
Copyright © 2025 Kenta Biotech AG
English (UK) English (US)